WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATCvet 5th levels 2024

 Updates included in the ATCvet Index valid from 2024.

ATCvet codeATCvet level name
QL02BX53abiraterone and prednisolone
QB01AD13apadamtase alfa and cinaxadamtase alfa
QC02KN01aprocitentan
QD11AH93atinvicitinib
QS01AA32bacitracin
QC05XX01beperminogene perplasmid
QC05XX90beraprost
QD03AX16beremagene geperpavec
QA10BK08bexagliflozin
QN06AX62bupropion and dextromethorphan
QB05XA19 1)calcium gluconate
QM09AX92canine stem cells
QL01EX27capivasertib
QJ01DE51cefepime and beta-lactamase inhibitor
QJ01DD58cefixime and beta-lactamase inhibitor
QJ01DC52cefuroxime and beta-lactamase inhibitor
QC01CA28centhaquine
QA01AB53chlorhexidine and cetylpyridinium
QS01HA08chloroprocaine
QL04AG90cirevetmab
QC04AX33clazosentan
QM04AC51colchicine and probenecid
QB02BX10concizumab
QL04AJ07crovalimab
QL04AJ09danicopan
QN05CJ03daridorexant
QL01BC58decitabine, combinations
QM09AX15delandistrogene moxeparvovec
QD11AH11delgocitinib
QS01BA16difluprednate
QL04AG15divozilimab
QN06DX05donanemab
QL03AA19eflapegrastim
QL01XX79eflornithine
QL02BA04elacestrant
QA16AB26eladocagene exuparvovec
QA05AX06elafibranor
QJ05AE16ensitrelvir
QL01FX27epcoritamab
QN07XX21eplontersen
QA07FA03escherichia coli
QB02BD16etranacogene dezaparvovec
QL04AE05etrasimod
QH05BX06evocalcet
QB06AX05exagamglogene autotemcel
QL01EK04fruquintinib
QL04AA90fuzapladib
QM09AX14givinostat
QL01FX28glofitamab
QN02AJ23hydrocodone and ibuprofen
QN02AJ22hydrocodone and paracetamol
QD11AH92ilunocitinib
QL01XX80imetelstat
QA10AE07insulin icodec
QL04AJ08iptacopan
QA02BX16irsogladine
QD11AH10lebrikizumab
QN06DX04lecanemab
QL03AX22leniolisib
QA16AX23leriglitazone
QL04AC25levilimab
QL01XL11lifileucel
QB01AC28limaprost
QL01XL08lisocabtagene maraleucel
QV04CX11lithium chloride
QS01CA12loteprednol and antiinfectives
QN02BA67magnesium salicylate, combinations excl. psycholeptics
QG03DB91melengestrol
QA10BD28metformin and teneligliptin
QL04AC24mirikizumab
QL01FX26mirvetuximab soravtansine
QL01EJ04momelotinib
QI10AB05moritella
QL01FX25mosunetuzumab
QL01XL10nadofaragene firadenovec
QM01AE57naproxen and diphenhydramine
QL01XX78navitoclax
QD11AH12nemolizumab
QL01XK52niraparib and abiraterone
QC01CX10omecamtiv mecarbil
QA02BC51omeprazole, combinations
QL01EL04orelabrutinib
QA16AB27pabinafusp alfa
QH05AA05palopegteriparatide
QS01XA31pegcetacoplan
QC10AB12pemafibrate
QN02AD51pentazocine and naloxone
QC09BX06perindopril, bisoprolol, amlodipine and indapamide
QC05AX06phenylephrine
QL01EL05pirtobrutinib
QS01AX24polihexanide
QM09AX91polyacrylamide
QI09AL09porcine rotavirus + escherichia + clostridium
QV03AB54pralidoxime and atropine
QL01FY03prolgolimab and nurulimab
QJ05AP13ravidasvir
QL04AF08ritlecitinib
QB01AF51rivaroxaban and acetylsalicylic acid
QD05AX06roflumilast
QC10BX21rosuvastatin and perindopril
QC10BX20rosuvastatin and telmisartan
QL04AG16rozanolixizumab
QR03AK15salbutamol and budesonide
QL03AB17sampeginterferon beta-1a
QL01FF12serplulimab
QA10BD29sitagliptin and dapagliflozin
QL01EX26sitravatinib
QI07AM04snake venom antiserum
QN07XX19sodium phenylbutyrate and ursodoxicoltaurine
QG04BX17sodium salicylate and methenamine
QB05XA20 2)sodium selenite
QJ05AR28stavudine and lamivudine
QL01FF11sugemalimab
QN02CC51sumatriptan and naproxen
QL01XL09tabelecleucel
QL01FX29talquetamab
QD05AX07tapinarof
QV09IA10technetium (99mTc) trofolastat chloride
QL01FX24teclistamab
QA10XX01teplizumab
QN07XX22tofersen
QL01FF13toripalimab
QN07XX23troriluzole
QA05AA05ursodoxicoltaurine
QB02BD15valoctocogene roxaparvovec
QH02AB18vamorolone
QG04BD15vibegron
QA02BD17vonoprazan and amoxicillin
QL04AJ06zilucoplan
QC09BX07zofenopril and nebivolol
1) Parenteral formulations should be classified here. Oral preparations should be classified in QA12AA03.
2) Parenteral formulations should be classified here. Oral preparations should be classified in QA12CE02.

Last updated: 2023-12-21